New Strategies in Sarcoma Therapy: Linking Biology and Novel Agents

The ability to better interrogate the genetic state of a given cancer is giving rise to a new paradigm in cancer therapeutics in which the specific genetic alterations that give rise to the cancer inform the therapeutic decision-making for that specific patient. Sarcomas of soft tissue and bone represent model diseases that underscore this paradigm. However, many barriers prevent linkage of one of the 75 or more different types of sarcoma to novel therapeutic agents. In the present perspective, the authors outline key therapeutic opportunities and hurdles in clinical sarcoma research, focusing on specific examples of sarcomas that are on the verge of new breakthroughs, as well as those in which promise has not lived up to expectations. Focused clinical trial design, ideally with several biomarker or histology-specific arms, is one means to be simultaneously parsimonious and inclusive. Clin Cancer Res; 18(21); 5837–44. ©2012 AACR.

[1]  D. Hawkins,et al.  Rhabdomyosarcoma: Review of the Children's Oncology Group (COG) soft‐tissue Sarcoma committee experience and rationale for current COG studies , 2012, Pediatric blood & cancer.

[2]  Andrew H. Beck,et al.  ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour , 2012, The Journal of pathology.

[3]  M. Lim,et al.  Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: A Children's Oncology Group phase I consortium study. , 2012 .

[4]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[5]  Arul M Chinnaiyan,et al.  PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. , 2012, Cancer research.

[6]  Aki Vehtari,et al.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.

[7]  Kevin B. Jones,et al.  Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. , 2012, Cancer cell.

[8]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[9]  J. Borgia,et al.  Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls , 2012, Therapeutic advances in medical oncology.

[10]  C. Weldon,et al.  Pediatric gastrointestinal stromal tumor. , 2012, Seminars in pediatric surgery.

[11]  P. Casali,et al.  A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  H. Joensuu,et al.  The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy. , 2012, Annual review of medicine.

[13]  C. Sander,et al.  Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. , 2011, Cancer discovery.

[14]  D. Reinke,et al.  R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  U. Dirksen,et al.  Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Flaherty,et al.  Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[17]  Marc Ladanyi,et al.  Advances in sarcoma genomics and new therapeutic targets , 2011, Nature Reviews Cancer.

[18]  P. Casali,et al.  Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  C. Rudin,et al.  Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Divya Pathania,et al.  Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. , 2011, Current pharmaceutical design.

[21]  D. Heymann,et al.  Mifamurtide for the treatment of nonmetastatic osteosarcoma , 2011, Expert opinion on pharmacotherapy.

[22]  C. Antonescu,et al.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.

[23]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[24]  Helen X. Chen,et al.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. , 2010, The New England journal of medicine.

[25]  T. Nielsen,et al.  EGR1 reactivation by histone deacetylase inhibitors promotes synovial sarcoma cell death through the PTEN tumor suppressor , 2010, Oncogene.

[26]  Derek Y. Chiang,et al.  Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy , 2010, Nature Genetics.

[27]  P. Choong,et al.  RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells , 2010, Clinical & Experimental Metastasis.

[28]  Marvin D Nelson,et al.  Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study , 2010, Pediatric blood & cancer.

[29]  David M. Thomas,et al.  Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. , 2010, The Lancet. Oncology.

[30]  David M. Thomas,et al.  Cancer‐associated neochromosomes: a novel mechanism of oncogenesis , 2009, BioEssays : news and reviews in molecular, cellular and developmental biology.

[31]  D. Hwang,et al.  Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Gorlick,et al.  Development of IGF-IR inhibitors in pediatric sarcomas , 2009, Current oncology reports.

[33]  I. Judson,et al.  Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[35]  T. Nielsen,et al.  Synergism of Heat Shock Protein 90 and Histone Deacetylase Inhibitors in Synovial Sarcoma , 2009, Sarcoma.

[36]  B. Pitard,et al.  Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma , 2010 .

[37]  F. Alt,et al.  Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. , 2008, Genes & development.

[38]  M. van de Rijn,et al.  Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. , 2008, Cancer research.

[39]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Heymann,et al.  Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. , 2007, Oncology reports.

[41]  B. Pitard,et al.  Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. , 2007, Cancer research.

[42]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Malay Haldar,et al.  A conditional mouse model of synovial sarcoma: insights into a myogenic origin. , 2007, Cancer cell.

[44]  B. Le Goff,et al.  Human osteosarcoma cells express functional receptor activator of nuclear factor‐kappa B , 2007, The Journal of pathology.

[45]  M. Ladanyi,et al.  SYT-SSX1 and SYT-SSX2 interfere with repression of E-cadherin by snail and slug: a potential mechanism for aberrant mesenchymal to epithelial transition in human synovial sarcoma. , 2006, Cancer research.

[46]  M. Capecchi,et al.  New genetic tactics to model alveolar rhabdomyosarcoma in the mouse. , 2005, Cancer research.

[47]  T. Nielsen,et al.  Hsp90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Prevents Synovial Sarcoma Proliferation via Apoptosis in In vitro Models , 2005, Clinical Cancer Research.

[48]  Michel Martinez,et al.  Most Wanted , 2005 .

[49]  J. Eary,et al.  FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma , 2003, Skeletal Radiology.

[50]  M. Ladanyi,et al.  Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. , 2001, The American journal of pathology.

[51]  S. Perkins,et al.  ALK1 and p80 Expression and Chromosomal Rearrangements Involving 2p23 in Inflammatory Myofibroblastic Tumor , 2001, Modern Pathology.

[52]  A. Albor,et al.  Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor , 1999, Oncogene.

[53]  K. Matthay,et al.  A Phase I/IB trial of murine monoclonal anti‐GD2 antibody 14.G2a plus interleukin‐2 in children with refractory neuroblastoma , 1997, Cancer.

[54]  C. Karakousis,et al.  Soft tissue sarcomas in adults , 1994, CA: a cancer journal for clinicians.

[55]  N. Cheung,et al.  Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. , 1987, Cancer research.

[56]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[57]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .

[58]  E. Kleinerman,et al.  Liposome-encapsulated muramyl tripeptide: a new biologic response modifier for the treatment of osteosarcoma. , 1993, Cancer treatment and research.

[59]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.